中国医科大学学报Issue(7)：648-652,5.
贝伐单抗联合顺铂治疗非小细胞肺癌恶性胸腔积液的临床研究
Clinical Research of Intrapleural Combination Therapy with Bevacizumab and Cisplatin for Non-small Cell Lung Cancer Mediated Malignant Pleural Effusion
曲博 1姜威 1周志明1
作者信息
- 1. 沈阳医学院附属中心医院胸外科，沈阳 110024
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and safety of combined intrapleural therapy with bevacizumab and cisplatin in controlling malignant pleural effusion(MPE)caused by non⁃small cell lung cancer(NSCLC). Methods A total of 63 NSCLC study subjects with MPE were randomly assigned to one of two groups(A and B). Group A(bevacizumab,n=32)received intrapleural bevacizumab(5 mg/kg)with cisplatin(40 mg/m2) therapy once a week for a total of three cycles. Group B(cisplatin,n=31)received intrapleural cisplatin therapy alone with the same dose and cycle. Pleural fluid was collected from both groups prior to and after treatment. The levels of VEGF in the pleural fluid were determined by ELISA. The cura⁃tive effect and adverse reaction were observed and follow⁃up was conducted. Results In 63 evaluable study subjects,the curative efficacy in the be⁃vacizumab group was significantly higher than that found in the cisplatin group(84.3%vs 61.3%,respectively,P<0.05). But the overall survival (OS)of the two groups showed no statistically significant difference(13.0 months vs 12.0 months,P>0.05). After treatment,The VEGF levels in the MPE were significantly decreased in both groups. In the bevacizumab group,the levels of VEGF in the pleural fluid were significantly lower com⁃pared to those of the cisplatin group after treatment,showing greater efficacy(P<0.05). The VEGF levels of the two groups whose treatment was in⁃valid had no statistically significant difference(P=0.079). There was no significant difference in gradeⅢ/Ⅳadverse events between the two groups. All procedures were well tolerated by the patients. Conclusion Combined intrapleural therapy with bevacizumab and cisplatin was effective and safe in managing NSCLC⁃mediated MPE. The patients showed high tolerance to the therapy. For prediction of local treatment efficacy of bevaci⁃zumab using the VEGF expression levels in MPE,further research was needed.关键词
非小细胞肺癌/恶性胸腔积液/血管内皮生长因子/贝伐单抗Key words
non-small-cell lung cancer/malignant pleural effusion/VEGF/bevacizumab分类
医药卫生引用本文复制引用
曲博,姜威,周志明..贝伐单抗联合顺铂治疗非小细胞肺癌恶性胸腔积液的临床研究[J].中国医科大学学报,2015,(7):648-652,5.
